LLY · News · 20260901N
Acquisition - Merida Biosciences
ELI LILLY & Co · 2026-09-01 · Importance 71 · Surprise 60 · No source text
Eli Lilly agreed to acquire immunology biotech Merida Biosciences for $2.9 billion. The transaction adds immunology assets to Lilly’s portfolio. It broadens the company’s pipeline beyond obesity and diabetes into additional growth areas.
Key facts
- Eli Lilly to buy Merida Biosciences in a $2.9B deal. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | probable | -1.0% | Eli Lilly to buy Merida Biosciences in a $2.9B deal. |